Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALMS
SELLAlumis Inc. · Healthcare · United States · $3.6B · Avg Vol: $44M/d
COMPANY DESCRIPTION
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel oral therapies for patients suffering from immune-mediated diseases. The company's competitive moat is built upon its proprietary drug discovery platform and a focused pipeline targeting specific immunological pathways with high unmet medical needs. It aims to differentiate through innovative treatments for chronic inflammatory conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 24.1M | — | 8.4M | 7.8M | 23.8M | -0.4% |
| EPS | -1.22 | -1.26 | -4.58 | -2.32 | — | -1.74 | -2.90 | -2.95 | — |
| Shares | 123.4M | 123.4M | 123.4M | 104.7M | -15.2% | 123.4M | — | — | — |
| Debt | 1.8M | 32.6M | 30.7M | 36.9M | 174.8% | 35.7M | — | — | — |
| Equity | -195.2M | -339.3M | 260.1M | 301.3M | 15.8% | — | — | — | — |
| Op CF | -107.7M | -130.0M | -255.1M | -369.5M | — | -376.2M | — | — | — |
| Inv CF | -68.8M | 60.5M | -113.8M | 287.9M | — | — | — | — | — |
| Fin CF | 101.6M | 89.7M | 492.4M | 2.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALMS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALMS | Alumis Inc.(you) | $3.6B | 22 | SELL |
| RCUS | Arcus Biosciences, Inc. | $3.6B | 22 | SELL |
| VKTX | Viking Therapeutics, Inc. | $4.0B | 21 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 26 | SELL |
| IRON | Disc Medicine, Inc. | $2.8B | 23 | SELL |
| LEGN | Legend Biotech Corporation | $4.3B | 24 | SELL |
| CLDX | Celldex Therapeutics, Inc. | $2.8B | 24 | SELL |
| GPCR | Structure Therapeutics Inc. | $3.5B | 15 | STRONG SELL |
| IDYA | IDEAYA Biosciences, Inc. | $3.4B | 29 | SELL |
| NKTR | Nektar Therapeutics | $2.4B | 22 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%